Loading

JSM Biochemistry and Molecular Biology

3-Hydroxypropanal (Reuterin) the Overlooked Cyclophosphamide Metabolite

Perspective | Open Access

  • 1. Institute of Biochemistry II. Goethe University Frankfurt Medical School, Frankfurt Germany
+ Show More - Show Less
Corresponding Authors
Georg Voelcker, Institute of Biochemistry II. Goethe University Frankfurt Medical School, Frankfurt Germany
INTRODUCTION

Cyclophosphamide (CP) is one of the oldest anticancer drugs, but one that is also highly effective by today’s standards. The theoretical idea for the development of CP was to administer a nontoxic prodrug that liberates in tumor tissue nitrogen mustard which damages DNA by alkylation. At the time, when CP was developed, it was believed that enzymes that catalyze splitting of phosphorus–nitrogen bonds (phosphoamidases) were preferentially found in tumor tissue [1,2]. This was the basis for the development of pro drugs from which alkylating nitrogen mustard should be split off in the target tissue “tumor”. Of the substances synthesized based on this theoretical requirement, CP proved to be the most effective in animal experiments. The theoretical concept was wrong, but the result was a very effective anticancer drug. 

Brief history of the metabolism of CP Very soon it turned out that CP is completely ineffective against tumor cells in vitro. Substances that kill tumor cells in vitro are only detectable in the blood after injection of CP. From the stable but therapeutically ineffective CP metabolites 4-ketocyclophosphamide (keto-CP) and carboxyphosphamide (CARB) found in the blood after CP injection, it was concluded that CP is hydroxylated by liver cytochrome P450 enzymes to form 4-hydroxycyclohosphamide (CPOH). which forms an equilibrium with its tautomer aldophosphamide (ALD) [3]. In vitro experiments in phosphate buffer solution with synthetically prepared CPOH showed that the alkylating agent was phosphoramide mustard (PAM) formed by β-elimination of acrolein from ALD [4]. PAM was assumed to kill cells by DNA alkylation. The detection of CPOH (Figure 1) after CP (Figure 1) injection was initially difficult because no reference substance was available.

Figure 1: Historical overview of the metabolism of CP

Figure 1: Historical overview of the metabolism of CP

After application of CP [1], in animals and patients, the stable but therapeutically ineffective metabolites ketocyclophosphamide [2], and CARB [6], were detected in the blood and urine. It was concluded that CP is hydroxylated by liver cytochrome P450 enzymes to give CPOH [2], which is in equilibrium with its tautomer ALD (2a). In vitro experiments with synthetic CPOH in buffer solutions showed that the alkylating agent PAM [3], is formed from ALD by ß-elimination of acrolein [4]. After intravenous injection of 100 mg/kg CP in mice, 92% is hydroxylated to CPOH. 80% of this is detoxified to Keto-CP and CARB [9].

Only after a synthesis for CPOH was developed [5], it was possible to prove CPOH in blood by thin layer chromatography and mass spectrometry [6,7], after CP injection. This was the state of knowledge about the metabolism of CP that had been frozen for decades and on which hypotheses about the mechanism of action and possibilities for improving the therapeutic effectiveness of CP were based. 

The two reactions competing for ALD, detoxification to CARB by aldehyde dehydrogenases (ALDH) and formation of PAM from ALD by β-elimination of acrolein have long been the focus of interest because they explain the different sensitivity of different tissues to CP. Cells with high ALDH activity such as intestinal mucosal cells, hematopoietic stem cells or occult tumor cells in bone marrow transplants [8], that can be eradicated with congeners of CP such as Mafosfamide (MF), which spontaneously hydrolyses to CPOH have low activity of ALDH. But attempts to explain thereby the tumor specificity of CP [8], were not convincing because by co-treatment with inhibitors of ALDH CP resistant tumors did not become CP sensible.

The old metabolite scheme of CP solidified over time because it was the basis for the very successful introduction of mercaptoethanesulfonic acid (Mesna) as an antidote to CP -and Ifosfamide (IF) toxicity. According to the old notion of CP metabolism, acrolein was the main cause of CP and IF dose limiting hemorrhagic cystitis, which is successfully treated with 2-mercaptoethanesulphonate (MESNA), It was believed that Mesna exert their toxicity-reducing effect by forming inert thioethers with acrolein [10].

Studies of the breakdown of CPOH in rat serum and proteinfree rat serum ultrafiltrate demonstrated that CPOH breaks down more than 100 times faster in rat serum than in rat serum ultrafiltrate. Phosphodiesterases (PDE) of the snake venom phosphodiesterase type (EC 3.1.4.1) were identified as the enzymes responsible for this decomposition. [11,12]. This was nothing exciting per se, but the whole thing became exciting when the reaction products of the decomposition of the tautomers CPOH/ ALDO were identified. The reaction products are not acrolein and PAM but PAM and 3-hydroxypropanal (HPA) [13]. However, at the time HPA was discovered as a CP metabolite it was assumed that HPA was only an insignificant intermediate product on the metabolic pathway to PAM, the discovery was not taken seriously. This is probably also why HPA did not fit into the worldview in which acrolein is the cause of hemorrhagic cystitis. The real cause of heorrhagic cystitis after CP and IF application is CPOH (IFOH) itself, which reacts with nucleophilic groups, e.g., SH groups of membrane proteins and is neutralized by Mesna [14].

Implications of the discovery of HPA as a CP metabolite for CP’s mechanism of action After the discovery of apoptosis, the view of the mechanism of action of alkylating substances changed. It has become apparent that any substance that damages DNA thereby initiates apoptosis. Schwartz and Waxman [15], investigated the effect of MF on the caspase 8 (extrinsic) and caspase 9 (intrinsic) dependent pathways of apoptosis in 9L tumor cells and 9L tumor cells transduced with CP hydroxylating CYP2B6. Contrary to other anticancer drugs like doxorubicin [16], and cisplatin [17], in which activation of caspase 8 is the initial apoptotic event, after application of MF, activation of caspase 9 was detectable before the activation of caspase 8. In addition caspase 9 was activated to a greater extent than caspase 8, indicating the p53 mediated apoptotic pathway, in response to upstream DNA damage, is triggered by CPOH released in minutes from MF. Seki et al came to the same conclusion, showing that. caspase 8 specific inhibitors only block cisplatin but not CP induced [16]. In the functional mechanism of alkylating agents, Schwartz and Waxman [15], distinguish between a cytostatic and a cytotoxic effect. In 9L cells, overexpressing the anti-apoptotic Bcl-2 protein, they could only determine the cytostatic effect after treatment with MF but no cytotoxic apoptosis. They state that the combination of CPOH induced DNA damage and Bcl-2 dependent cytotoxic response is necessary for cell death. The mentioned reports clearly demonstrate that the functional mechanism of OHCP is bimodal: First occurs the cytostatic DNA damage by PAM and, secondly, the cytotoxic p53 mediated apoptosis is observed. The second step is critical because it can be manipulated by factors that affect the pathway of apoptosis. Such a factor is very likely HPA, one of the two reaction products of the enzymatic decomposition of OHCP. HPA, also known as reuterin, is produced by Lactobacillus reuteri and submitted to the culture medium. It has been shown to be active against bacteria viruses and fungi [18], it is used as food additive to prevent spoilage by growth of pathogens. Experiments by Iyer [19], who investigated the effects of the supernatant of L. reuteri cultures (LR) on tumor necrosis factor (TNF)-activated apoptosis signaling pathways in human leukemia cells, showed that reuterin inhibits (i) the formation of the anti-apoptotic proteins Bcl-2 and Bcl-xL and (ii) the TNF dependent NF-κB activation by inhibition of the translocation of the p65 subunit of NF-κB into the nucleus. The experiments of Iyer et al. further showed that the degradation of IκBα by lack of the ubiquitination of IκBα is suppressed by the supernatant of LR. Thus, by the inhibition of the nuclear translocation of NF-κB apoptosis is enhanced [19]. 

In summary, the scientific literature gives the following picture:

1. The event leading to cell death after CP application is not DNA damage but apoptosis triggered by DNA damage [5].

2. The CP metabolite HPA is an apoptosis enhancer. This leads to the action scheme of CP and other OX shown in (Figure 3)

 

Cite this article

Voelcker G (2022) 3-Hydroxypropanal (Reuterin) the Overlooked Cyclophosphamide Metabolite. JSM Biochem Mol Biol 8(1): 1038.

EXPERIMENTAL EVIDENCE FOR PRESENTED MECHANISM OF ACTION OF CP AND OTHER OX

In experiments on regional perfusion of the tumor-bearing limb in rats, CPOH proved to be completely ineffective in contrast to systemic therapy with CP [20, 21]. This was despite the fact that the CPOH concentration in the perfusate (oxygenated hemoglobin solution) at the point of entry into the rat leg (a. epigastric superficialis) was about 100 times higher than after CP application. The amount of CPOH taken up by the tissue was 12 times greater in the perfusion experiments than after systemic therapy with CP [22].

In perfusion experiments with nitrogen mustard N-oxide, which has a comparable effect to PAM, and in experiments with cisplatin, the animals were cured. The reason for the failure of the perfusion experiments with CPOH was clearly that the perfusion solution did not contain ALD-splitting PDE.

CP was “found” by a happy coincidence. It is not tailor-made for the reaction scheme in Figure 3.

Figure 2 The real metabolism of CP.

Figure 2: The real metabolism of CP.

PAM [3] is formed from ALD (2a) by enzymatic cleavage of ALD by phosphodiesterases (PDE). This creates HPA [7].

Figure 3 Mechanism of action of CP and other OX

Figure 3: Mechanism of action of CP and other OX

CP (and other OX) is hydroxylated by P450 enzymes in the liver to CPOH from which a small part is oxidized to keto-CP. CPOH is in equilibrium with its tautomere ALD. ALD is the pharmacologic active metabolite. The bulk of it is oxidized by ALDH to the nontoxic CARB. The amount of ALD not oxidized, is decomposed by phosphodiesterase (PDE) to the alkylating PAM and proapoptotic HPA. PAM damages DNA by alkylation. The alkylated DNA is either repaired immediately or, if this is not possible, the tumor suppressor protein p53 is activated, which induces cell cycle stop to give the cell time to repair the damage. If DNA repair is not possible, p53 induces apoptosis, which is - and this is special for CP and other OX - enhanced by HPA which supports apoptosis by inhibiting the anti-apoptotic proteins Bcl-2 and Bcl-xL, and by inhibiting NF-κB activation. Additional HPA promotes apoptosis by enhancing mitogen-activated protein kinase (MAPK) activities by enhancing JNK and p38 phosphorylations.

Disadvantages are the individually varying hydroxylation by cyt. p450 enzymes in the liver, the formation of toxic CPOH en route to the pharmacologically active metabolite ALD, and the lack of adaptation of the alkylating function for DNA damage that initiates optimal apoptosis exploitation. To correct the first two CP “design errors” mentioned, tiazolidine and perhydrothiazines were synthesized from aldophosphamide and I-aldophosphamide, which hydrolyze spontaneously, bypassing toxic CPOH (IFOH) to ALD (IALD) [23] (Figure 4).

These compounds are nine fold lower toxic than CPOH and more effective than the parent compounds CP and IF against subcutaneously transplanted P388 tumors in mice [23]. A special feature of the thiazolidine compounds is that the thiazolidine ring gives them the ability to cross the blood-brain barrier [24]. Because the perhydrothiazine of I-aldophosphamide (8 fig.4 R1=R2= -CH2CH2Cl, R3=H, n=2) is easy to synthesize and easy to handle, further experiments with this compound (I-aldophosphamide perhydrothiazine, IAP ) were carried out.

Another construction flaw of CP - the lack of adaptation to the initiation of apoptosis - can be corrected as follows: According to the scheme (Figure 3), the apoptosis yield is greater, the lower the amount of alkylated DNA that is repaired by the cell’s own repair mechanisms. According to Povirk and Shuker [25], chlorethyl groups as found in IAP form interstrand cross links. whereas methane sulfonate groups form intrastrand cross-links [22]. In contrast to interstrand cross-links, intrastrand cross-links are poorly repaired

(http://www.atdbio.com/content/16/Nucleic-acid-druginteractions).

If in the IAP molecule (Figure 4) in the residue R1 -CH2CH2Cl the chlorine is substituted by a sulfonyl methyl group (R1 is now -CH2 CH2 OSO2 CH3 ), a perhydrothiazine derivative called SUM-IAP is obtained. SUM-IAP is in cell culture experiments with P388 mice leukemia cells significantly less cytotoxic than IAP but against the same cells when growing as solid tumors in mice 104 - 105 times more effective than IAP [26].

Figure 4 Spontaneous hydrolysis of thiazolidines (8 n=1) and perhydrothiazines (8 n=2) from aldophosphamide (8 R1 =H, R2 =R3 = -CH2 CH2 Cl) and I-aldophosphamide (8 R1 =R2 = -CH2 CH2 Cl, R3 =H) to ALD (2a) and L-cys (9 n=1) or homocysteine (9 n=2).

Figure 4: Spontaneous hydrolysis of thiazolidines (8 n=1) and perhydrothiazines (8 n=2) from aldophosphamide (8 R1 =H, R2 =R3 = -CH2 CH2 Cl) and I-aldophosphamide (8 R1 =R2 = -CH2 CH2 Cl, R3 =H) to ALD (2a) and L-cys (9 n=1) or homocysteine (9 n=2).

These experimental results - the failure of CPOH in regional perfusion of the tumor-bearing limb in rats and the enormous increase in antitumor effect when repair of the alkylated DNA is prevented - are a strong indication that the scheme in (Figure 3) is correct.

One can discuss whether HPA, the long-neglected CP metabolite, makes CP, long classified as an alkylating cytostatic, to a new class of cytostatics, the class of apoptosis boosters.

REFERENCES

1. Meyer J, Weinmann JP. Phosphamidase content of normal and pathologic tissues of the oral cavity. J Histochem Cytochem. 1953; 1: 305- 314.

2. Tomita K, Takeuchi T. On the phosphamidase reaction of tumor tissues. Gan. 1955; 46: 333-334.

3. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol. 1974; 23: 115-129.

4. Struck RF, Kirk MC, Mellett LB, el Dareer S, Hill DL. Urinary metabolites of the antitumor agent cyclophosphamide. Mol Pharmacol. 1971; 7: 519-529.

5. Peter G. Wagner T, Hohorst HJ. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): A simple preparation method and its application for the synthesis of a new class of “activated” sulfur-containing cyclophosphamide (NSC-26271) derivatives. Cancer Treat Rep. 1976; 60: 429-435.

6. Voelcker G. Wagner T. Hohorst HJ. Identification and pharmacokinetics of cyclophosphamide (NSC26271) metabolites in vivo. Cancer Treat Rep. 1976; 60: 415-422.

7. Przybylski M, Ringsdorf H, Voelcker G, Draeger U, Peter G, Hohorst HJ. Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry. Cancer Treat Rep. 1976; 60: 509-16.

8. Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood. 1995; 85: 2742-6.

9. Voelcker G, Haeglsperger R. Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of “activated” cyclophosphamide (4-hydroxycyclophosphamide) (author’s transl). Arzneimittelforschung. 1982; 32: 639-647.

10.Brock N, Pohl J, Stekar J. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. J Cancer Res Clin Oncol. 1981; 100:3 11-20.

11.Voelcker G, Bielicki L, Hohorst HJ. Evidence for enzymatic toxification of actitivated cyclophosphamide (4-hydroxycyclophosphamide). 1981, J Can Res Clin Oncol 99A, 58-59.

12.Bielicki L, Voelcker G, Hohorst HJ. Enzymatic toxicogenation of activated cyclophosphamide by 3´-5´exonucleases. J Canc Res Clin Oncol.1983; 105: 27-29.

13.Voelcker G. Enzyme catalyzed decomposition of 4-hydroxycyclophosphamide. Open Conf Proc J. 2017; 8: 44-51.

14.Voelcker G. Causes and possibilities to circumvent cyclophosphamide toxicity. Anti-Cancer Drugs. 2020; 31: 617-622.

15.Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001; 60: 1268- 1279.

16.Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Tasaka K. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol. 2000; 45: 199-206.

17.Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res.1998; 58: 4453-4460.

18.Cleusix V, Lacroix C, Vollenweider S, Duboux M, Le Blay G. Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria. BMC Microbiol. 2007; 7: 101.

19.Iyer C, Kosters A, Sethi G, Kunnumakkara AB, Aggarwal BB, Versalovic J. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappa B and MAPK signalling. Cell Microbiol. 2008; 10: 1442-1452.

20.Erven G. Vergleichende Untersuchungen über die Antitumorwirkung von stabilisierten, aktivierten Cyclophosphamid und cis Platin am Modell des tumortragenden Rattenbeins durch regionale Perfusion. Inauguraldissertation zur Erlangung des Doktorgrades beim Fachbereich Veterenärmedizin der Justus-Liebig-Universität Gießen (1986).

21.Skupin W. Die regionale Perfusion des tumortragenden Rattenbeins mit stabilisierten, aktivierten Cyclophosphamiden in Kombina¬tion mit Protektorthiolen. Inauguraldissertation zur Erlangung des Doktorgrades beim Fachbereich Veterenärmedizin der Justus- LiebigUniversität Gießen (1990).

22.Voelcker G. Mechanism of Action of Oxazaphosphorine Cytostatics Demonstrated by Regional Perfusion of the Tumor-Bearing Limb in Rats with 4-Hydroxycyclophosphamide. EC PHARMACOLOGY AND TOXICOLOGY. 2022.

23.Voelcker G, Bielicki L, Hohorst HJ. Thiazolidinyl-and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation. J Cancer Res Clin Oncol. 1997; 123: 623-631.

24.Jungkamp W. Aktive anreicherung von aldophosphamid thiazolidincarbonsäure in tierischen zellen untersuchungen an ehrlich-ascitestumorzellen.

25.Inaugural-dissertation zur erlangung des doktorgrades der zahnmedizin des fachbereichs humanmedizin der johann wolfgang goethe universität frankfurt am main 1990.

26.Povirk LF, Shuker DE. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res. 1994; 31: 205-226.

27.Voelcker G, Pfeiffer B, Schnee A, Hohorst H.J. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine. Cancer Res Clin Oncol. 2000; 126: 74-8.

Voelcker G (2022) 3-Hydroxypropanal (Reuterin) the Overlooked Cyclophosphamide Metabolite. JSM Biochem Mol Biol 8(1): 1038

Received : 12 Oct 2022
Accepted : 03 Nov 2022
Published : 05 Nov 2022
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
TEST Journal of Dentistry
ISSN : 1234-5678
Launched : 2014
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X